A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis

Thrombosis and Haemostasis

Volumn 97, Issue 1, 2007, Pages 54-61

  Wang, Yi Xin ^a   da Cunha, Valdeci ^a   Vincelette, Jon ^a   Zhao, Lei ^a   Nagashima, Mariko ^a   Kawai, Kohichi ^a   Yuan, Shendong ^a   Emayan, Kumar ^a   Islam, Imadul ^a   Hosoya, Junko ^a   Sullivan, Mark E ^a   Dole, William P ^a   Morser, John ^a   Buckman, Brad O ^a   Vergona, Ronald ^a  

^a BAYER AG   (Germany)

Author keywords

Bleeding; Dog; Fibrinolysis; Rabbit; Rat; TAFI; Thombolysis; Thrombosis

Indexed keywords

BATROXOBIN; BX 528; CARBOXYPEPTIDASE; FERROUS CHLORIDE; LIPOPOLYSACCHARIDE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOT LYSIS; COMBINATION CHEMOTHERAPY; DOG; DOSE RESPONSE; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; EX VIVO STUDY; FIBRIN DEPOSITION; FIBRINOLYSIS; LASER COAGULATION; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; THROMBOGENESIS; THROMBOGENICITY; THROMBOSIS; THROMBUS;

ANIMALS; CARBOXYPEPTIDASE U; DISEASE MODELS, ANIMAL; DOGS; DRUG SYNERGISM; ENZYME INHIBITORS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; LIPOPOLYSACCHARIDES; PROPIONIC ACIDS; RABBITS; RATS; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33846947189     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-09-0552     Document Type: Article

References (27)

1. Nesheim M, et al. Modulation of fibrin cofactor activity in plasminogen activation. Ann NY Acad Sci 2001; 936: 247-60.
2. Bouma BN, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-54.
3. Schatteman K, et al. Carboxypeptidase U at the interface between coagulation and fibrinolysis. Clin Appl Thromb Hemost 2001; 7: 93-101.
4. Nesheim M. Myocardial infarction and the balance between fibrin deposition and removal. Ital Heart J 2001; 2: 641-5.
5. Mattsson C, et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002; 87: 557-62.
6. van Tilburg NH, et al. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
7. Klement P, et al. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.
8. Nagashima M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
9. Paoni NF, et al. Involvement of residues 296-299 in the enzymatic activity of tissue-type plasminogen activator. Protein Eng 1992; 5: 259-66.
10. Wu C, et al. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003; 90: 414-21.
11. Zhao L, et al. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity. J Biol Chem 2003; 278: 32359-66.
12. Wang YX, et al. Lipopolysaccharide attenuates thrombolysis in batroxobin-induced lung vasculature fibrin deposition but not in ferrous chloride-induced carotid artery thrombus in rats: role of endogenous PAI-1. Thromb Res 2003; 111: 381-7.
13. Pirkle H, et al. Thrombin-like enzymes from snake venoms: an inventory. For the Subcommittee on Nomenclature of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1991; 65: 444-50.
14. Bell WR, Jr. Defibrinogenating enzymes. Drugs 1997, 54 (Suppl 3): 18-30; discussion-1.
15. Stone GW, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636-41.
16. Brodie BR, et al. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000; 85: 13-8.
17. Zijlstra F. Acute myocardial infarction: primary angioplasty. Heart 2001; 85: 705-9.
18. Chesebro JH, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-54.
19. Simes RJ, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91: 1923-8.
20. Anderson HV. Restenosis after coronary angioplasty. Dis Mon 1993; 39: 613-70.
21. Lenderink T, et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group. Circulation 1995; 92: 1110-6.
22. Schneider M, et al. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J Thromb Haemost 2003; 1: 147-54.
23. Walker JB, et al. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J Biol Chem 2003; 278: 8913-21.
24. Minnema MC, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
25. Suzuki K, et al. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2- [(R)-2-methyl-1-(3-phenylpropanoylamino) propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004; 309: 607-15.
26. Nagashima M, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
27. Nagashima M, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. Front Biosci 2002; 7: d556-68.